Hypothalamic-pituitary function following bromocriptine therapy in patients with prolactinomas.

Area of Science:

• Endocrinology
• Reproductive Medicine

Background:

• Prolactinomas are pituitary tumors that cause hyperprolactinemia, leading to menstrual irregularities and infertility.
• Current treatments aim to reduce prolactin levels and tumor size.

Purpose of the Study:

• To evaluate the efficacy of bromocriptine in treating prolactinomas.
• To assess its effects on prolactin levels, menstrual function, fertility, and pituitary hormone reserve.

Main Methods:

• 18 patients with prolactinomas received 5 mg of bromocriptine daily.
• Serum prolactin levels and prolactin response to TRH stimulation were monitored.
• Pituitary hormone reserve was assessed.
• Pregnancy outcomes were recorded.

Main Results:

• Serum prolactin normalized in 95% of patients within 12 weeks.
• Bromocriptine significantly altered prolactin response to TRH stimulation.
• No significant changes in other pituitary hormones were observed.
• Seven pregnancies resulted in healthy deliveries, including twins.

Conclusions:

• Bromocriptine is effective in normalizing prolactin levels and restoring fertility in patients with prolactinomas.
• Further studies on pituitary hormone monitoring during maintenance therapy are recommended.
• Bromocriptine may be a valuable treatment for fertility in prolactin-secreting microadenomas.